According to a new report published by Introspective Market Research, titled, Peptic Ulcer Drugs Market by Drug Class, Indication, and Distribution Channel,” the Global Peptic Ulcer Drugs Market Size Was Valued at USD 34.42 Billion in 2023 and is Projected to Reach USD 49.84 Billion by 2032, Growing at a CAGR of 4.2% from 2024 to 2032. The Peptic Ulcer Drugs Market focuses on medications that aid in the prevention and treatment of ulcers in the stomach and upper intestinal lining caused by Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs (NSAIDs), and excessive acid production. These drugs include proton pump inhibitors (PPIs), H2 receptor antagonists, antibiotics, and antacids, which work by reducing gastric acid secretion and promoting mucosal healing.
With the rising prevalence of gastrointestinal disorders globally, driven by stress, unhealthy dietary habits, and widespread NSAID use, the demand for peptic ulcer therapies continues to expand. Additionally, technological advancements in drug formulations, such as delayed-release and combination therapies, are enhancing treatment effectiveness. The market is further supported by growing healthcare expenditure, better diagnostic rates, and strong pharmaceutical R&D investments targeting safer and more efficient ulcer management solutions.
The Peptic Ulcer Drugs Market is segmented into Drug Class, Indication, and Distribution Channel. By Drug Class, the market is categorized into Proton Pump Inhibitors (PPIs), H2-Receptor Antagonists, Antibiotics, Antacids, and Others. By Indication, it is segmented into Gastric Ulcer, Duodenal Ulcer, and Esophageal Ulcer. By Distribution Channel, it is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.
A major growth driver for the Peptic Ulcer Drugs Market is the rising prevalence of Helicobacter pylori infections and increasing NSAID consumption worldwide. Sedentary lifestyles, stress, and poor eating habits have increased the incidence of peptic ulcers, particularly in aging populations. Moreover, widespread use of over-the-counter pain relievers has contributed to gastrointestinal complications, necessitating effective ulcer treatments. Growing healthcare access and awareness in emerging economies further accelerate drug adoption, supporting steady market growth.
A key opportunity for the market lies in the development of novel combination therapies and next-generation PPIs with improved efficacy and reduced side effects. Biopharmaceutical innovations, including targeted antibiotics and mucosal protective agents, are expected to open new growth avenues. Additionally, the expansion of online pharmacy channels and the availability of generic alternatives are making treatments more affordable and accessible. Increasing R&D collaboration between pharmaceutical companies also offers potential for innovation and regional market expansion.
Peptic Ulcer Drugs Market, Segmentation
The Peptic Ulcer Drugs Market is segmented on the basis of Drug Class, Indication, and Distribution Channel.
Drug Class:
The Drug Class segment is further classified into Proton Pump Inhibitors (PPIs), H2-Receptor Antagonists, Antibiotics, Antacids, and Others. Among these, the Proton Pump Inhibitors (PPIs) segment accounted for the highest market share in 2023. PPIs remain the first-line therapy for acid suppression and ulcer healing due to their superior efficacy in inhibiting gastric acid secretion, longer duration of action, and extensive physician preference. Their widespread availability as both prescription and OTC formulations supports their dominance.
Distribution Channel:
The Distribution Channel segment is categorized into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Among these, Retail Pharmacies held the largest market share in 2023, driven by their easy accessibility and growing consumer preference for over-the-counter ulcer medications. Increasing partnerships between retail chains and drug manufacturers have also improved product availability across developed and emerging markets.
Some of The Leading/Active Market Players Are
- AstraZeneca plc (United Kingdom)
- Pfizer Inc. (United States)
- GlaxoSmithKline plc (United Kingdom)
- Takeda Pharmaceutical Company Limited (Japan)
- Eisai Co., Ltd. (Japan)
- Boehringer Ingelheim International GmbH (Germany)
- Daewoong Pharmaceutical Co., Ltd. (South Korea)
- Johnson & Johnson (United States)
- Sun Pharmaceutical Industries Ltd. (India)
- Dr. Reddy’s Laboratories Ltd. (India)
- Cadila Healthcare Ltd. (India)
- Bayer AG (Germany)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Lupin Pharmaceuticals (India)
- and other active players.
Key Industry Developments
-
In June 2024, Takeda Pharmaceutical launched an advanced proton pump inhibitor formulation in Japan to provide faster ulcer healing and improved patient compliance.
This new PPI version enhances bioavailability and reduces the risk of drug interactions, strengthening Takeda’s gastroenterology product portfolio. - In March 2023, AstraZeneca announced a strategic collaboration with a biotech firm to develop next-generation anti-ulcer therapies targeting Helicobacter pylori resistance.
The partnership focuses on creating antibiotic combinations with enhanced stability and reduced adverse effects, aiming to address rising antimicrobial resistance challenges.
Key Findings of the Study
- Proton Pump Inhibitors (PPIs) dominated the market in 2023.
- Retail pharmacies accounted for the highest distribution share.
- Asia-Pacific and North America are the leading regional markets.
- Growing H. pylori prevalence and lifestyle changes drive market demand.
- R&D for combination and next-gen ulcer drugs offers growth potential.
